Last week, the U.S. Patent Trial and Appeal Board took a long-term Gilenya patent out of commission, putting the Novartis multiple sclerosis drug in line for early generic competition.
Right now, Novartis' Sandoz has the only biosimilar on the U.S. market. And it's looking to make it two.
A month removed from launching the U.S.'s first biosimilar, Novartis is again setting sights on an Amgen cash cow, lining up for FDA approval with a copy of the blockbuster Enbrel.
Xoma has worked a deal to outlicense a cancer antibody to its longtime partners at Novartis. In the deal Xoma will get $37 million in badly needed cash upfront, some relief on $13.5 million in debt and the chance to earn $480 million in milestones, if all goes as planned.
Novartis is chasing a pair of new uses for brand-new psoriasis med Cosentyx, and when it comes to psoriatic arthritis, it's piling up the positive data.
The U.S. Patent and Trademark Office's review board has dealt its first blow to Big Pharma. The appeal panel nixed a patent on Novartis' multiple sclerosis blockbuster Gilenya, handing a win to challenger Torrent Pharmaceuticals--and fellow generics makers Mylan and Apotex, which had filed a separate challenge.
Novartis has issued a voluntary recall of more than 10,000 bottles of a drug used to treat attention deficit hyperactivity disorder (ADHD) that were manufactured at a plant in Georgia.
Batman and Superman can add another superhero to their ranks at publisher DC Comics, and that's Scott. The teenage protagonist and his trusty sidekick--Turbo the toy dog--feature in the company's latest graphic novel, which Novartis partnered to create for teens with tuberous sclerosis complex.
Novartis has predicted that its launch of newly FDA-approved heart failure med Entresto would be its "most exciting" ever. And now, it's one step closer to bringing that excitement to Europe.
Mark Fishman, head of Novartis' $10 billion research operation, is retiring next year, making way for an award-winning Harvard oncologist after 13 years at the helm.